Renaissance Technologies’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
PCH
SCM
FLAM
O
DCM
AC
Renaissance Technologies's NPCE Position: Q2 2026 in Review
Renaissance Technologies reduced its Neuropace (NPCE) stake by 36% in Q2 2026, selling an estimated $1.01M and leaving 111,699 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2028.
Renaissance Technologies first reported a position in NPCE in Q2 2022 and has held it in 17 quarters since. The position peaked at $3.43M in Q4 2025. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.
- Renaissance Technologies held 111,699 shares of Neuropace worth $1.77M as of Q2 2026.
- Renaissance Technologies sold 62,612 Neuropace shares in Q2 2026, an estimated $1.01M.
- Neuropace made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2028 holding.
- Renaissance Technologies first reported a position in Neuropace in Q2 2022 and has held it in 17 quarters since.
- Renaissance Technologies's Neuropace position peaked at $3.43M in Q4 2025.
- 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.